Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020



Paul Lloyd-Evans

Paul Lloyd-Evans

Head of Clinical Biotechnology Centre, NHS
Head of NHSBT’s Clinical Biotechnology Centre and having nearly 30 years experience working in research and development laboratories and 15 of those specialising in Advanced Therapies. Appointed Head of CBC in 2007 and responsible for the overall management of the facility and 20 staff. The CBC is part of NHSBT’s Cell and Molecular Therapies function and specialises in the small scale GMP manufacture of clinical grade gene therapy such as plasmid DNA and recombinant protein products. Graduated in 1984 before undertaking a PhD in Immunology and further post-doctoral studies at the University of Wales. In 1993 joined NHSBT as a Clinical Scientist in antibody engineering and became Deputy and Development Scientist at the CBC in 2001. This challenging role included the development and transfer of processes compliant to GMP. To date publications include 24 peer-reviewed papers and research articles.
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd